Cancer Research

Heavy-chain-only antibody
#Antibody #Cancer Research UK #KisoJi Biotechnology #Oncology #Phase I trial

First patient receives novel heavy-chain-only antibody

Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours.  The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody.  TROP2 is a transmembrane glycoprotein involved in… Read More

#Cancer Research #News

Cytokine release syndrome
#Clinical trial #Cytokine Release Syndrome (CRS) #Immunotherapy #Myeloma #Oncology

New drug could improve access to immunotherapies

A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma.  The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More

#Cancer Research #News

Radioactive containers
#Oncoinvent #Oncology #Phase I trial #Radiopharmaceuticals

Radiotherapeutic study shows low exposure to healthy organs

Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine.  The publication reports results from nine patients enrolled in the dosimetry cohorts of the Phase I Radspherin studies, which… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer Research UK Manchester Institute #Dendritic cells #Immunotherapy #Oncology

Scientists unmask immune cells that supercharge the fight against cancer

A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute, have found. Their discovery, published in Immunity, centres on activated dendritic cells, a specialised population of immune cells that orchestrate the body’s… Read More

#Cancer Research #Editor's Choice #News

Breast cancer
#Breast cancer #Oncology #Roswell Park Comprehensive Cancer Center #Sethera Therapeutics

Award validates collaborative breast cancer research project

A collaborative breast cancer research project has received funding through the Fiscal Year 2025 Breast Cancer Research Program Breakthrough Award, administered by the Congressionally Directed Medical Research Programs (CDMRP).   The award recognises the scientific merit, innovation, and collaborative strength of the research teams led by Dr Katerina… Read More

#Cancer Research #News

X-ray showing colon cancer
#Dispatch Bio #Gastrointestinal cancer #Immunotherapy #Oncology #Phase I trial #Solid tumours

New therapy targets blocks to immunotherapy success in solid tumours

Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma.   The participant was treated with both DV-10 and ide-cel… Read More

#Cancer Research #News

Colorectal cancer
#Colorectal cancer #Oncology #Phase I trial #The Institute of Cancer Research

Targeted therapy shows promise in advanced colorectal cancer

A targeted antibody therapy combined with standard chemotherapy has shown early signs of tumour shrinkage and disease control in patients with advanced bowel cancer.  This is according to new Phase I clinical trial results from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cells
#Funding #Oncology #Pancreatic cancer

$6.7m awarded to pancreatic cancer research projects

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is awarding $6.7 million to eight projects in 2026.  The funded projects span the full continuum of pancreatic cancer research, from prevention and early detection to next-generation therapies.   “Every investment we make is driven by one goal:… Read More

#Cancer Research #News

Radiopharmaceutical drug
#European Medicines Agency #Oncology #Orphan drugs #Perspective Therapeutics #Radiopharmaceuticals

Perspective receives European orphan medicinal product designation

Radiopharmaceuticals company Perspective Therapeutics has received orphan medicinal product designation from the European Commission (EC) for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).  The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).  “Patients with unresectable or metastatic… Read More

#Cancer Research #News #Regulatory

Antibodies attack Covid-19
#Covid-19 #Dendritic cells #Immunity #Oncology

Scientists redirect Covid-19 immune memory to fight cancer

Scientists have developed a novel cancer vaccine platform that transforms the synchronised mass immune memory generated through SARS-CoV-2 infection and vaccination into a powerful ally against cancer.  The study by scientists from Celloram, University Hospitals, and Case Western Reserve University was published in Nature Communications. Read More

#Cancer Research #Editor's Choice #News

AI and robotics
#Artificial intelligence (AI) #Computational chemistry #Deep Origin #Lymphoma #Oncology

AI validates molecular glue compound that kills lymphoma cells

Deep Origin’s docking and molecular dynamics (MD) simulations have successfully rationalised researchers’ work identifying a potent compound to switch on cell-death programmes in diffuse large B cell lymphoma (DLBCL).  The study was led by researchers at Stanford University and the University of Texas MD Anderson Cancer Center. … Read More

#Cancer Research #News

Lung cancer
#Kairos Pharma #Lung cancer #Monoclonal antibodies #Oncology

New drug could change post-progression treatment of EGFR-NSCLC

Kairos Pharma has shared interim safety data from its ongoing Phase I clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca’s Tagrisso) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The company says the data represent a pivotal milestone in its lead programme: resensitising patients… Read More

#Cancer Research #News

#Cancer drug targets #Clinical trial #DNA #Kairos Pharma #Prostate cancer #Stem cells #Tumour biology

Cancer drug resistance isn’t one problem, it’s many

Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it.  Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes durable clinical success. That problem is drug resistance. Therapies that… Read More

#Cancer Research #Exclusive Content

Modern medical science laboratory
#AI #France #spatial

Bioptimus partners with French cancer research organisation 

AI tech company Bioptimus has signed a partnership with one of France’s leading academic cancer research organisations in efforts to build an AI model of biology.  The partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) will grant Bioptimus access to a unique cohort of deeply phenotyped clinical trial data from more than 3,000 gastrointestinal (GI)… Read More

#Cancer Research #News